Veterinary Medicines

Wellplus Flavoured Tablets

Authorised
  • Febantel
  • Pyrantel embonate
  • Praziquantel
Download as PDF

Product identification

Medicine name:
Wellplus Flavoured Tablets
Wellplus comprimidos palatáveis para cães
Active substance:
  • Febantel
  • Pyrantel embonate
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    150.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    144.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA30
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Available in:
  • Portugal
Package description:
  • box containing 300 tablets (30 blisters)
  • box containing 100 tablets (10 blisters)
  • box containing 50 tablets (5 blisters)
  • box containing 20 tablets (2 blisters)
  • box containing 10 tablets (1 blister)
  • box containing 2 tablets (1 blister)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Divasa Farmavic S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • DIVASA-FARMAVIC, S.A.
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 738/01/13DFVPT
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0163/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Germany
  • Greece
  • Ireland
  • Netherlands
  • Poland
  • Portugal
  • Slovakia
  • United Kingdom (Northern Ireland)

Documents

eu-PUAR-wellplus-flavoured-tablets-en.pdf

English (PDF)
Published on: 11/04/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."